Dual MNK/VEGFR2 Inhibitor JDB153 Enhances Immunotherapeutic Efficiency and Chemosensitivity in Lung Cancer

Abstract

Lung cancer continues to be the primary cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. Dysregulation of protein translation that participates in cell proliferation is an important factor to define oncogenic processes and cancer development. The eukaryotic initiation factor 4E (eIF4E) regulates ribosomal translation of proteins from mRNA, and the mitogen-activated protein kinase interacting kinases (MNKs) is reported to be the only kinases that can phosphorylate eIF4E. Substantial previous work has proven that the MNK–eIF4E axis is usually dysregulated in many cancer types. Moreover, abnormal angiogenesis is essential for tumorigenesis and cancer progression, and vascular endothelial growth factors (VEGF) together with their receptors play multiple crucial roles in angiogenesis, especially VEGFR2. In this study, we report a novel dual MNK/VEGFR2 inhibitor named JDB153 and investigate its antitumor effects in NSCLC. JDB153 can effectively inhibit the phosphorylation of eIF4E and VEGFR2, suppress proliferation, migration and invasion, promote apoptosis, and induce cycle arrest of lung cancer cells. Importantly, JDB153 exhibits antitumor activity and synergizes with anti-PD-1 therapy and cisplatin with reliable safety. Our findings reveal the potential value of JDB153 in lung cancer as monotherapy or in combination with immunotherapy and chemotherapy, with the hope to provide a novel combinational strategy for NSCLC treatment clinically.

Keywords

eIF4F / inhibitor / JDB153 / lung cancer / MNK / VEGFR2

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[2] A. Leiter, R. R. Veluswamy, and J. P. Wisnivesky, “The Global Burden of Lung Cancer: Current Status and Future Trends,” Nature Reviews Clinical Oncology 20, no. 9 (2023): 624-639.

[3] F. Janku, D. J. Stewart, and R. Kurzrock, “Targeted Therapy in Non-Small-Cell Lung Cancer-Is It Becoming a Reality?,” Nature Reviews Clinical Oncology 7, no. 7 (2010): 401-414.

[4] M. Yuan, L. L. Huang, J. H. Chen, J. Wu, and Q. Xu, “The Emerging Treatment Landscape of Targeted Therapy in Non-small-Cell Lung Cancer,” Signal Transduct Target Ther 4 (2019): 61.

[5] D. S. Ettinger, D. E. Wood, D. L. Aisner, et al., “NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023,” Journal of the National Comprehensive Cancer Network 21, no. 4 (2023): 340-350.

[6] D. R. Camidge, R. C. Doebele, and K. M. Kerr, “Comparing and Contrasting Predictive Biomarkers for Immunotherapy and Targeted Therapy of NSCLC,” Nature Reviews Clinical Oncology 16, no. 6 (2019): 341-355.

[7] L. Fabbri, A. Chakraborty, C. Robert, and S. Vagner, “The Plasticity of mRNA Translation During Cancer Progression and Therapy Resistance,” Nature Reviews Cancer 21, no. 9 (2021): 558-577.

[8] N. Sonenberg and A. G. Hinnebusch, “Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets,” Cell 136, no. 4 (2009): 731-745.

[9] Y. Xu and D. Ruggero, “The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications,” Annual Review of Cancer Biology 4, no. 1 (2020): 437-457.

[10] A. G Hinnebusch. The Scanning Mechanism of Eukaryotic Translation Initiation. In: Kornberg RD ed. Annual Review of Biochemistry (2014): 779-812.

[11] C. G. Proud, “Mnks, eIF4E Phosphorylation and Cancer,” Biochimica Et Biophysica Acta (BBA)—Gene Regulatory Mechanisms 1849, no. 7 (2015): 766-773.

[12] X. Chen, Y. An, M. Tan, D. Xie, L. Liu, and B. Xu, “Biological Functions and Research Progress of eIF4E,” Frontiers in Oncology 13 (2023).

[13] M. Bartish, M. J. Abraham, C. Gonçalves, O. Larsson, C. Rolny, and S. V. del Rincón, “The Role of eIF4F-driven mRNA Translation in Regulating the Tumour Microenvironment,” Nature Reviews Cancer 23, no. 6 (2023): 408-425.

[14] H. Suzuki, J. Lu, H. Zang, et al., “Overexpression of p-Akt, p-mTOR and p-eIF4E Proteins Associates With Metastasis and Unfavorable Prognosis in Non-small Cell Lung Cancer,” PLoS ONE 15, no. 2 (2020).

[15] Q. Dong, L. Dong, S. Liu, Y. Kong, M. Zhang, and X. Wang, “Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients With Non-Small Cell Lung Cancer,” Medical Science Monitor 26 (2020): e923210.

[16] C. Pinto-Díez, R. Ferreras-Martín, R. Carrión-Marchante, V. M. González, and M. E. Martín, “Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer,” International Journal of Molecular Sciences 21, no. 8 (2020): 2967.

[17] M. Buxade, J. L. Parra-Palau, and C. G. Proud, “The Mnks: MAP Kinase-interacting Kinases (MAP kinase signal-integrating kinases),” Frontiers in Bioscience-Landmark 13 (2008): 5359-5373.

[18] S. Diab, M. Kumarasiri, M. Yu, et al., “MAP Kinase-Interacting Kinases—Emerging Targets Against Cancer,” Chemistry & Biology 21, no. 4 (2014): 441-452.

[19] T. Ueda, M. Sasaki, A. J. Elia, et al., “Combined Deficiency for MAP Kinase-interacting Kinase 1 and 2 (Mnk1 and Mnk2) Delays Tumor Development,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 32 (2010): 13984-13990.

[20] T. N. D. Pham, C. Spaulding, and H. G. Munshi, “Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity,” Cancers 12, no. 8 (2020): 2096.

[21] S. Liu, J. Zha, and M. Lei, “Inhibiting ERK/Mnk/eIF4E Broadly Sensitizes Ovarian Cancer Response to Chemotherapy,” Clinical and Translational Oncology 20, no. 3 (2017): 374-381.

[22] M. Grzmil, J. Seebacher, D. Hess, et al., “Inhibition of MNK Pathways Enhances Cancer Cell Response to Chemotherapy With Temozolomide and Targeted Radionuclide Therapy,” Cellular Signalling 28, no. 9 (2016): 1412-1421.

[23] Y. Liu, Y. Li, Y. X. Wang, et al., “Recent Progress on Vascular Endothelial Growth Factor Receptor Inhibitors With Dual Targeting Capabilities for Tumor Therapy,” Journal of Hematology & Oncology 15, no. 1 (2022): 89.

[24] G. Liu, T. Chen, Z. Ding, Y. Wang, Y. Wei, and X. Wei, “Inhibition of FGF-FGFR and VEGF-VEGFR Signalling in Cancer Treatment,” Cell Proliferation 54, no. 4 (2021): e13009.

[25] K. P. Claffey, L. F. Brown, L. F. delAguila, et al., “Expression of Vascular Permeability Factor Vascular Endothelial Growth Factor by Melanoma Cells Increases Tumor Growth, Angiogenesis, and Experimental Metastasis,” Cancer Research 56, no. 1 (1996): 172-181.

[26] F. Gao and C. Yang, “Anti-VEGF/VEGFR2 Monoclonal Antibodies and Their Combinations With PD-1/PD-L1 Inhibitors in Clinic,” Current Cancer Drug Targets 20, no. 1 (2020): 3-18.

[27] G. Mountzios, J. Remon, L. E. L. Hendriks, et al., “Immune-checkpoint Inhibition for Resectable Non-small-cell Lung Cancer—opportunities and Challenges,” Nature Reviews Clinical Oncology 20, no. 10 (2023): 664-677.

[28] J. E. Chaft, A. Rimner, W. Weder, C. G. Azzoli, M. G. Kris, and T. Cascone, “Evolution of Systemic Therapy for Stages I-III Non-metastatic Non-small-cell Lung Cancer,” Nature Reviews Clinical Oncology 18, no. 9 (2021): 547-557.

[29] X. C. Chen, Y. An, M. S. Tan, D. R. Xie, L. Liu, and B. J. Xu, “Biological Functions and Research Progress of eIF4E,” Frontiers in Oncology 13 (2023): 1076855.

[30] T. J. Laskowski, A. Biederstädt, and K. Rezvani, “Natural Killer Cells in Antitumour Adoptive Cell Immunotherapy,” Nature Reviews Cancer 22, no. 10 (2022): 557-575.

[31] S. K. Wculek, F. J. Cueto, A. M. Mujal, I. Melero, M. F. Krummel, and D. Sancho, “Dendritic Cells in Cancer Immunology and Immunotherapy,” Nature Reviews Immunology 20, no. 1 (2019): 7-24.

[32] C. Aggarwal, C. D. Rolfo, G. R. Oxnard, J. E. Gray, L. M. Sholl, and D. R. Gandara, “Strategies for the Successful Implementation of Plasma-based NSCLC Genotyping in Clinical Practice,” Nature Reviews Clinical Oncology 18, no. 1 (2021): 56-62.

[33] Q. Dong, L. L. Dong, S. Liu, Y. Kong, M. Zhang, and X. W. Wang, “Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients With Non-Small Cell Lung Cancer,” Medical Science Monitor 26 (2020): e923210.

[34] A. Yoshizawa, J. Fukuoka, S. Shimizu, et al., “Overexpression of Phospho-eIF4E Is Associated With Survival Through AKT Pathway in Non-Small Cell Lung Cancer,” Clinical Cancer Research 16, no. 1 (2010): 240-248.

[35] Q. Guo, M. Bartish, C. Gonçalves, et al., “The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer,” Cancer Research 81, no. 14 (2021): 3876-3889.

[36] M. Cerezo, R. Guemiri, S. Druillennec, et al., “Translational Control of Tumor Immune Escape via the eIF4F-STAT1-PD-L1 Axis in Melanoma,” Nature Medicine 24, no. 12 (2018): 1877-1886.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.